FAM107B

Across TCGA pan-cancer cohorts, FAM107B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM107B data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FAM107B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM107B expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where FAM107B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.577	0.306	.006	26	view →
CCRCC	DFS	Median	All	0.627	0.861	.001	23	view →
HNSC	DFS	Median	III,IV	0.704	0.900	.009	22	view →
UCEC	DFS	Quartile	All	1.000	0.804	.006	14	view →
OV	DFS	Median	All	1.000	0.850	.037	4	view →
LUAD	OS	Median	All	0.616	0.867	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FAM107B–PDAC (DFS)

Open the PDAC breakdown →